Patient Recruitment AI Stack

Why Patient Recruitment Is the Costliest Bottleneck in Clinical Trials

Eighty percent of clinical trials fail to meet their enrollment timelines. Thirty percent of enrolled patients drop out before the trial concludes. And for every day a trial runs behind schedule, sponsors lose an estimated $600,000 to $8 million in unrealized revenue.

Patient recruitment isn't just a logistical problem — it's the single largest cost and timeline driver in clinical development. The traditional approach — site coordinators manually reviewing charts, running database queries, and making phone calls — simply can't scale to meet the complexity of modern trial designs. Protocols now require narrow subgroups, specific biomarker profiles, and diverse populations across multiple geographies.

The Recruitment Problem: What AI Is Actually Solving

Patient-trial matching at scale. AI tools parse structured data (diagnoses, labs, medications) and unstructured data (clinical notes, radiology reports, pathology findings) to identify candidates who meet complex eligibility criteria — in minutes rather than weeks.

Prescreening accuracy. AI-powered NLP can process the full depth of a patient's medical record, including free-text clinical notes that structured queries can't access, achieving 93–96% accuracy in eligibility determination.

Diversity and representativeness. Regulatory agencies increasingly require trial populations that reflect the diversity of the intended treatment population. AI tools can identify eligible patients across underrepresented demographic groups and geographies, flagging diversity gaps before they become compliance issues.

Continuous matching. Traditional recruitment is a point-in-time activity. AI enables continuous patient matching — as new patients enter the health system and their records are updated, they're automatically evaluated against active trial criteria.

Retention prediction. Some platforms now predict which enrolled patients are at risk of dropping out, enabling proactive interventions before the loss occurs.

The Recommended Patient Recruitment AI Stack

Layer 1: EHR Mining and Patient-Trial Matching — Deep 6 AI (Tempus)

Deep 6 AI, acquired by Tempus in March 2025, is the leading AI platform for EHR-based patient recruitment. It uses NLP and machine learning to mine structured and unstructured electronic medical record data — including clinical notes, pathology reports, and radiology findings — to match patients to complex eligibility criteria in real time.

The platform's reach is substantial: access to EMR data from 30 million patients, 30,000+ healthcare professionals, and thousands of active trials across leading research institutions, including six NCI-designated cancer centers.

Deep 6 AI demonstrated a 170x speed improvement at Cleveland Clinic, identifying eligible trial candidates in minutes versus hours of manual review, with 96% accuracy. Since the Tempus acquisition, the platform benefits from Tempus's broader precision medicine infrastructure, including genomic data integration.

Alternative: Mendel.ai specializes in oncology trial matching using clinical-genomic data, strong in precision oncology where biomarker-driven eligibility criteria are complex.

Layer 2: Patient Engagement and Direct Matching — Antidote (Elligo Health Research)

Antidote takes the patient-facing approach to recruitment. Rather than mining institutional EHRs, Antidote connects patients directly to trials through digital matching technology. Patients register, provide health information, and receive notifications about relevant studies.

Antidote partners with over 1,000 patient advocacy organizations and health communities. This approach is particularly valuable for disease areas with strong patient advocacy communities (oncology, rare diseases, neurology) and for reaching patients who don't receive care at major academic medical centers.

Alternative: Trialbee, European-headquartered with strong GDPR compliance, uses AI to match patients from EHR, insurance claims, and real-world data sources. Good choice for global trials requiring European recruitment.

Layer 3: Feasibility, Site Selection, and Enrollment Analytics — TriNetX

TriNetX (covered in detail in the Protocol Design stack) extends naturally into recruitment. Its federated network of 300+ million patient records enables site identification — showing you exactly which healthcare organizations are caring for your target patient population, with projections for how many eligible patients will present over the next 12 months.

For recruitment specifically, TriNetX's AI-powered cohort analytics let you model enrollment scenarios: what happens to your recruitment timeline if you add a site in Brazil? If you relax one exclusion criterion? If a competing trial opens at three of your top-performing sites?

Alternative: Phesi uses digital patient profiles and AI-driven simulations to forecast enrollment by geography and site.

Implementation Guide

Step 1: Connect recruitment to protocol design. If you've followed the Protocol Design stack, your eligibility criteria have already been pressure-tested against real-world patient populations using TriNetX. The validated criteria become the input for your recruitment tools.

Step 2: Deploy EHR mining at your trial sites. Start with Deep 6 AI at your highest-priority sites. Focus on sites where enrollment has historically lagged — the AI matching will have the highest impact where manual processes are most strained.

Step 3: Layer patient engagement for hard-to-reach populations. For trials in rare diseases, or where your sites don't have sufficient patient volume, add Antidote's patient engagement platform. The combination of institutional EHR mining plus direct patient outreach covers both supply-side and demand-side recruitment.

Step 4: Monitor and optimize with enrollment analytics. Use TriNetX's enrollment forecasting to track recruitment velocity against your timeline. When sites underperform, the analytics can diagnose why and recommend corrective actions.

ROI and Evidence

• Deep 6 AI demonstrated 170x speed improvement in patient identification at Cleveland Clinic, with 96% accuracy
• TriNetX clients report 20%+ reduction in protocol amendments through criteria pressure-testing, which directly reduces recruitment restarts
• AI-powered recruitment can increase enrollment rates by up to 20% and cut development timelines by an average of 6 months per asset
• A 12-month reduction in clinical development is worth over $400 million in net present value for a single development program
• Antidote's network of 1,000+ patient advocacy partnerships reaches populations that traditional site-based recruitment misses entirely

Compliance callout

Patient recruitment tools access protected health information (PHI) for matching. Deep 6 AI operates under BAAs and applies HIPAA-compliant de-identification before any data leaves the source system. AI-driven patient matching may qualify as human subjects research under your IRB — confirm whether your institution requires a protocol amendment or separate IRB review. See our AI Compliance section for detailed guidance.

---

This guide is part of the ClinStacks AI Stack series. View all stacks → · Previous: Protocol Design → · Next: Data Management →